Showing 1 - 10 of 50
The Bureau of Labor Statistics' Prescription Drug Consumer Price Index (CPI-Rx) has been the focus of considerable controversy in recent years. The CPI-Rx limits its sampling frame to transactions in retail outpatient outlets, and excludes prescription pharmaceuticals dispensed in hospitals,...
Persistent link: https://www.econbiz.de/10013388804
Persistent link: https://www.econbiz.de/10000920438
Persistent link: https://www.econbiz.de/10000821041
Persistent link: https://www.econbiz.de/10011405980
Persistent link: https://www.econbiz.de/10001767928
Persistent link: https://www.econbiz.de/10001133174
Persistent link: https://www.econbiz.de/10000922444
Drug pricing in the U.S. is a persistently vexing policy problem. While there is agreement among many policy analysts that supra competitive prices are necessary to promote innovation; significant disagreements arise over how much pricing discretion prescription drug manufacturers should be...
Persistent link: https://www.econbiz.de/10012929016
Persistent link: https://www.econbiz.de/10011796655
Empirical studies suggest that entry of generic competitors results in minimal decreases or even increases in brand-name drug prices as well as sharp declines in brand-name advertising. This paper examines circumstances under which this empirical pattern could be observed. The analysis focuses...
Persistent link: https://www.econbiz.de/10012475193